Please try another search
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company’s program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Name | Age | Since | Title |
---|---|---|---|
Joel Castellanos | - | 2021 | Member of Scientific Advisory Board |
P. Gage Jull | 63 | 2020 | Independent Chairman of the Board |
Robin L. Carhart-Harris | - | 2021 | Chairman of Scientific Advisory Board |
Derek Ott | - | - | Member of Scientific Advisory Board |
Daniel J. Clauw | - | 2021 | Member of Scientific Advisory Board |
Peter Molloy | 51 | 2023 | Chief Business Officer & Director |
James S. Kuo | 59 | 2019 | Co-Founder & Director |
Rachel Wevrick | - | - | Member of Scientific Advisory Board |
William K. Schmidt | 73 | 2021 | Member of Scientific Advisory Board |
Jason Carroll | - | 2023 | CEO & Director |
Christopher Leo Ntoumenopoulos | 40 | 2022 | Independent Non Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review